Aptorum Group LtdAPMEarnings & Financial Report
Nasdaq · Health Care · Measuring & Controlling Devices, NEC
Aptorum Group Ltd is a global biopharmaceutical enterprise dedicated to researching, developing and commercializing innovative therapeutic and diagnostic solutions. Its core focus areas cover infectious diseases, women’s health, and rare disorders, with key markets spanning North America and the Asia-Pacific region.
APM Q4 FY2025 Key Financial Metrics
Revenue
$442.8K
Gross Profit
N/A
Operating Profit
$-232.8K
Net Profit
$-282.5K
Gross Margin
N/A
Operating Margin
-52.6%
Net Margin
-63.8%
YoY Growth
N/A
EPS
$-0.04
Aptorum Group Ltd Q4 FY2025 Financial Summary
Aptorum Group Ltd reported revenue of $442.8K for Q4 FY2025, with a net profit of $-282.5K (-63.8% margin). Cost of goods sold was N/A.
Key Financial Metrics
| Total Revenue | $442.8K |
|---|---|
| Net Profit | $-282.5K |
| Gross Margin | N/A |
| Operating Margin | -52.6% |
| Report Period | Q4 FY2025 |
Aptorum Group Ltd Quarterly Revenue & Net Profit History
Aptorum Group Ltd results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $442.8K | — | $-282.5K | -63.8% |
| Q3 FY2025 | $208.8K | — | $-614.0K | -294.0% |
| Q2 FY2023 | $431.4K | — | $-5.5M | -1272.0% |
Income Statement
| Q2 2023 | Q3 2025 | Q4 2025 | |
|---|---|---|---|
| Revenue | $431378 | $208843 | $442820 |
| YoY Growth | N/A | N/A | N/A |
Balance Sheet
| Q2 2023 | Q3 2025 | Q4 2025 | |
|---|---|---|---|
| Assets | $14.4M | $17.6M | $18.7M |
| Liabilities | $1.6M | $4.4M | $4.9M |
| Equity | $21.8M | $22.5M | $23.1M |
Cash Flow
| Q2 2023 | Q3 2025 | Q4 2025 | |
|---|---|---|---|
| Operating CF | $-6.2M | $-484283 | $-145861 |